Diamedica Therapeutics Inc (DMAC) Stock Price, Quote & News

Company Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 496 5454

Website: www.diamedica.com

Address:

301 Carlson Parkway, Suite 210, Minneapolis, United States

Sukitt Jun. 28 at 3:53 AM

$DMAC Look at the volume today. Incredible. Russell index inclusion sign.

0 · Reply

Sicksir Jun. 24 at 1:34 PM

$DMAC https://www.stocktitan.net/news/DMAC/dia-medica-therapeutics-announces-inclusion-in-the-russell-2000-and-pahrx3sbv4tc.html DiaMedica Added to Russell 2000 Index Ahead of Key Phase 2 Data | DMAC Stock News

0 · Reply

justiceforb_85 Jun. 6 at 2:50 AM

$DMAC possible update this month on rinvecalinase in pre-eclampsia?

0 · Reply

Tjcmd May. 31 at 1:49 AM

$DMAC couldn’t understand a word of the first KOL speaker so I turned it off…

1 · Reply

Tjcmd May. 21 at 6:45 PM

$DMAC Listened to HCW call. 90% of time/questions on pre-eclampsia. P1a will be to determine if (and/or how much) crosses placenta (drug will be given just before delivery). Then P1b will be given early on to determine if drug can delay (and by how many days) need for early delivery (current SOC only gives additional 5 days so babies still being delivered prematurely). WRT to AIS no mention of CMO absence and no mention of interim replacement. Too bad because Dr. Masuoka seemed highly competent.

0 · Reply

MedCred May. 19 at 2:30 PM

$DMAC DM 199 for Preeclampsia. KOL over the next couple of weeks. https://www.businesswire.com/news/home/20250519893700/en/ The data must be good !!!

1 · Reply

Tjcmd May. 14 at 6:33 PM

$DMAC disappointed on enrollment progress for AIS. On last CC they mentioned 2 factors that would speed up pace: 1. Changing from frozen to refrigerated drug (can enroll after hours since no pharmacist needed to thaw) 2. Include patients who have failed TPA therapy (after wash out period) The fact they did not have an interim CMO or at least the neurologist who is filling in (unnamed) is concerning to me. Seems like the pre-eclampsia indication has now assumed the lead indication over AIS and I’m wondering why (bigger TAM?) Anyone else have concerns after the call?

1 · Reply

Tjcmd May. 14 at 5:54 PM

$DMAC anyone know whats up with CMO illness? She was great on last CC…why didn’t they give the neurologist name?

1 · Reply

MedCred May. 14 at 1:49 PM

$DMAC sounded positive on the preeclampsia trial. Didn’t release data though. Would like to have heard at least some positive news reading between the lines ….The fact that they are having a KOL talk in late May means they must know good data. Otherwise. Why bother

0 · Reply

Sicksir May. 13 at 9:00 PM

$DMAC https://www.diamedica.com/investors/press-releases/detail/1701/diamedica-therapeutics-reports-first-quarter-2025-financial Preliminary topline safety and efficacy results from Part 1A of the trial are anticipated between the second half of June and the first half of July, depending on turnaround time for laboratory test results.

0 · Reply

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

May 22, 2025, 8:30 AM EDT - 5 weeks ago

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

May 19, 2025, 9:00 AM EDT - 5 weeks ago

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

May 14, 2025, 4:30 PM EDT - 6 weeks ago

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

May 14, 2025, 11:05 AM EDT - 6 weeks ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:30 PM EDT - 6 weeks ago

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

May 8, 2025, 4:00 PM EDT - 7 weeks ago

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

May 7, 2025, 8:30 AM EDT - 7 weeks ago

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

Mar 18, 2025, 10:27 AM EDT - 3 months ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:30 PM EDT - 3 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

Mar 11, 2025, 8:23 AM EDT - 3 months ago

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Feb 24, 2025, 8:30 AM EST - 4 months ago

DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of Directors

Feb 20, 2025, 8:15 AM EST - 4 months ago

DiaMedica Therapeutics Announces Publication of DM199's Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

Feb 10, 2025, 4:15 PM EST - 4 months ago

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 3, 2024, 8:25 AM EST - 7 months ago

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

Nov 14, 2024, 12:49 PM EST - 8 months ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:20 PM EST - 8 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 8 months ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Nov 12, 2024, 8:23 AM EST - 8 months ago

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

Nov 6, 2024, 8:32 AM EST - 8 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Oct 9, 2024, 8:27 AM EDT - 9 months ago

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Sep 4, 2024, 4:15 PM EDT - 10 months ago

DiaMedica Therapeutics Upcoming Conference Participation

Aug 7, 2024, 4:15 PM EDT - 11 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

Aug 1, 2024, 8:20 AM EDT - 11 months ago

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

Jul 11, 2024, 2:48 PM EDT - 1 year ago

DiaMedica: Early 2025 Interim Futility Analysis Could Be A Major Inflection Point

Jul 11, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Jul 1, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

Jun 26, 2024, 8:15 AM EDT - 1 year ago

DiaMedica Therapeutics Announces $11.8 Million Private Placement

Jun 26, 2024, 8:00 AM EDT - 1 year ago

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

May 11, 2024, 4:49 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:30 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 2, 2024, 8:55 AM EDT - 1 year ago

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

Apr 17, 2024, 4:08 PM EDT - 1 year ago

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Mar 20, 2024, 4:14 PM EDT - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:15 PM EDT - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Jan 29, 2024, 4:13 PM EST - 1 year ago

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Jan 22, 2024, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Nov 14, 2023, 12:10 PM EST - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:28 PM EST - 1 year ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Nov 9, 2023, 8:25 AM EST - 1 year ago

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Nov 6, 2023, 8:23 AM EST - 1 year ago

DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023

Sep 12, 2023, 8:13 AM EDT - 1 year ago

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Sep 6, 2023, 8:35 AM EDT - 1 year ago

DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference

Aug 15, 2023, 3:43 PM EDT - 2 years ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript

Aug 14, 2023, 4:13 PM EDT - 2 years ago

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 8:32 AM EDT - 2 years ago

DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023

Jul 18, 2023, 8:30 AM EDT - 2 years ago

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Jun 26, 2023, 8:30 AM EDT - 2 years ago

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Jun 21, 2023, 8:39 AM EDT - 2 years ago

DiaMedica Therapeutics Announces $37.5 Million Private Placement

Jun 21, 2023, 8:15 AM EDT - 2 years ago

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

Sukitt Jun. 28 at 3:53 AM

$DMAC Look at the volume today. Incredible. Russell index inclusion sign.

0 · Reply

Sicksir Jun. 24 at 1:34 PM

0 · Reply

justiceforb_85 Jun. 6 at 2:50 AM

$DMAC possible update this month on rinvecalinase in pre-eclampsia?

0 · Reply

Tjcmd May. 31 at 1:49 AM

$DMAC couldn’t understand a word of the first KOL speaker so I turned it off…

1 · Reply

Tjcmd May. 21 at 6:45 PM

0 · Reply

MedCred May. 19 at 2:30 PM

$DMAC DM 199 for Preeclampsia. KOL over the next couple of weeks. https://www.businesswire.com/news/home/20250519893700/en/ The data must be good !!!

1 · Reply

Tjcmd May. 14 at 6:33 PM

1 · Reply

Tjcmd May. 14 at 5:54 PM

$DMAC anyone know whats up with CMO illness? She was great on last CC…why didn’t they give the neurologist name?

1 · Reply

MedCred May. 14 at 1:49 PM

0 · Reply

Sicksir May. 13 at 9:00 PM

0 · Reply

Armonica423 May. 10 at 8:13 PM

$DMAC Big exposure for CYDY at 3 oncology conferences this upcoming week, do your dd research

0 · Reply

MedCred May. 7 at 3:04 PM

$DMAC silence. Must be planning to announce data from preeclampsia trial soon. Surely it’s complete. Possibly with earnings release next week ???

1 · Reply

RJRNAB Apr. 30 at 10:45 AM

$DMAC 5.99 premarket?

1 · Reply

Viter Apr. 28 at 6:17 PM

$DMAC some.news is coming?

0 · Reply

justiceforb_85 Apr. 23 at 1:56 AM

$DMAC wondering if we have any data for rinvecalinase in either pre-eclampsia or stroke?

0 · Reply

eneub87 Apr. 15 at 12:35 PM

$DMAC that was strange..

0 · Reply

Whiskey1679 Apr. 9 at 11:23 AM

$TNMG Above average volume. 90 day low is 0.50 / 90 day high is $2.52. $WLGS Not a lot of volume. The 90 day low is 0.21. 90 day high is $9.66. For Newbies: Remember STOP Loss only works after the 6:30 am PDT bell and not after the market closes at 1:00 pm PDT. Pre Market Gappers: $CRWS $EDAP $DMAC

0 · Reply

Stmkr Apr. 7 at 1:12 PM

$DMAC what happened here?

0 · Reply

Viter Apr. 3 at 9:09 AM

$DMAC https://d1io3yog0oux5.cloudfront.net/_128b0adc408dd02d603ee990ef5963b3/diamedica/db/202/3208/pdf/DMAC+Corporate+Presentation+-+April+2025.pdf

0 · Reply

nailman Mar. 23 at 5:30 PM

$DMAC same old, same old

2 · Reply

Market Cap	164.67M
Revenue (ttm)	0.00
Net Income (ttm)	-24.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,185,200
Avg Vol	175,074
Day's Range	N/A - N/A
Shares Out	42.88M
Stochastic %K	50%
Beta	1.23
Analysts	Strong Sell
Price Target	$9.67